Forxiga

Selected form

Dapagliflozin

Method of action: Antidiabetic, Drugs Used In Diabets

Treatment option: Diabetes Mellitus, Type 2 Diabetes

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Forxiga

Quick Facts

Property	Description
Active Ingredient	Dapagliflozin
Form	Film-coated tablets
Pharmacological Class	SGLT2 Inhibitor
Common Use	Improving blood glucose control
Origin	Synthetic compound

Forxiga is a specific, prescription-only medicinal product, distinguished from over-the-counter agents, that is used to support metabolic and cardiovascular health. Its core identity is the active substance Dapagliflozin (INN), which is provided in the fixed, single-component dosage of a film-coated tablet taken via the oral route.

What Type of Medicine is Forxiga and Its Active Ingredient?

The active ingredient in Forxiga is the compound Dapagliflozin, which is technically a synthetic C-glycosyl derivative. The formulation as an oral medication is clinically recognized for ensuring the consistent and reliable systemic delivery of the drug, which is essential for its long-term management applications. In the United States, the same active substance is marketed under the brand name Farxiga, but the chemical composition and therapeutic action remain consistent.

Forxiga's Unique Pharmacological Classification

Forxiga belongs to a specialized and modern pharmacological class of drugs known as Sodium-Glucose Co-transporter 2 (SGLT2) inhibitors, classified under the WHO's Anatomical Therapeutic Chemical (ATC) code A10BK01. This classification places it among the oral blood glucose lowering drugs. The mechanism is distinct because it operates entirely independent of insulin activity. This non-traditional approach is effective in settings where insulin functionality may be compromised.

What is the General Therapeutic Purpose of Dapagliflozin?

The general therapeutic purpose of Dapagliflozin is to help achieve improved glycaemic control and offer protective support to the heart and kidneys. It works by causing the selective inhibition of the SGLT2 protein found in the kidney tubules. This action results in a therapeutic increase of urinary glucose excretion. This is the fundamental way the medicine lowers overall blood sugar concentration and contributes to its wider cardiorenal benefits, which are typically utilized as part of a patient's long-term management plan.

Regulatory References

Forxiga (Dapagliflozin) EPAR

What side effects are possible with Forxiga?

Possible side effects and safety information

The safety profile for dapagliflozin (Forxiga) is formally categorized based on incidence rates observed in clinical studies and post-marketing surveillance, consistent with regulatory standards. The adverse reactions are grouped into categories such as Infections and Infestations, Metabolism and Nutrition Disorders, and Renal and Urinary Disorders.

Adverse reactions classified as Common include female genital mycotic infections (e.g., vulvovaginitis), urinary tract infections (UTIs), polyuria (increased urination), dizziness, and reactions related to volume depletion (such as hypotension or dehydration). The risk of hypoglycaemia (low blood sugar) is classified as Very Common only when dapagliflozin is used in combination with insulin or insulin secretagogues.

Classification	Examples of Reactions
Common	Genital infections, UTIs, Volume depletion, Polyuria
Rare/Very Rare	Diabetic Ketoacidosis (DKA), Fournier's gangrene

Official labeling documents serious, clinically significant events, including Diabetic Ketoacidosis (DKA), which is documented as rare. A very rare but serious adverse event is Necrotising fasciitis of the perineum (Fournier's gangrene). Specific safety considerations are noted for certain populations; for instance, older adults and those with renal impairment may have an increased risk of volume-related adverse reactions. Furthermore, the label notes that the drug causes interference with diagnostic tests, resulting in a positive urine glucose test due to its mechanism.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory information for Forxiga (dapagliflozin) addresses the management of overdose and the identification of severe acute conditions that require immediate medical attention.

Condition / Manifestation	Immediate Action Required by Regulators
Diabetic Ketoacidosis (DKA) Symptoms	Stop taking the medication and seek medical attention immediately.
Severe Volume Depletion/Hypotension	Call a healthcare provider or go to the nearest emergency room right away.
Necrotizing Fasciitis	Stop taking the medication and seek medical attention immediately.

Documented Overdose Presentations and Risks

Official labeling describes that symptoms of DKA, such as nausea, vomiting, abdominal pain, trouble breathing, or unusual tiredness, require urgent medical evaluation. The risk of DKA exists even when blood glucose levels are not extremely high (euglycemic DKA). Overdose or acute events may also lead to volume depletion and symptomatic hypotension (low blood pressure), which has been linked to cases of acute kidney injury.

Emergency Response and Monitoring

If more tablets are taken than prescribed, patients are instructed to call a healthcare provider or go to the nearest hospital emergency room right away. Immediate medical help is required for any signs of DKA, severe allergic reaction (e.g., angioedema), or signs of the serious infection Necrotizing Fasciitis of the Perineum (pain, tenderness, or swelling in the genital/perineal area, often with fever).

Management of a confirmed overdose is symptomatic and supportive. There is no known specific antidote. Supportive care includes monitoring volume status and treating any resulting metabolic acidosis or DKA (typically with insulin and fluid replacement).

Therapeutic Uses of Forxiga

What Forxiga Treats: Main Uses and Benefits

Forxiga (dapagliflozin) is a medication that supports the management of conditions across three major chronic domains: metabolic, cardiac, and renal health. The medicine is used for managing conditions such as Type 2 Diabetes, Chronic Heart Failure, and Chronic Kidney Disease in adults, and in some cases, children and adolescents. Its role is to provide long-term support for these chronic conditions, contributing to the easing of associated symptoms and supportive risk management.

The medication is commonly used across conditions presenting with systemic discomfort and is considered relevant for patients with persistently high blood sugar, symptomatic heart failure, or a risk of functional strain on the kidneys. It supports the management of symptoms related to systemic imbalance, such as excessive thirst and fatigue from poor glycemic control, and also helps address symptom clusters that may become disruptive, such as breathlessness and fluid accumulation linked to cardiac stress.

“The treatment may assist with maintaining a sense of stability and contributes to easing the overall symptom load during periods of heightened discomfort.”

This support may assist with supportive risk management related to cardiovascular outcomes, including supporting the reduction in the risk of hospitalization for heart failure events, and assists with maintaining functional stability over time by helping to address symptoms linked to organ-specific functional stress.

Quick Fact: Supportive Role in Symptom Management
Supports managing symptoms related to Systemic Hyperglycemia, Cardiovascular Volume Overload, and functional strain on the kidneys.

Regulatory References

European Medicines Agency

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Forxiga — Official Regulatory Information

Forxiga's eligibility is determined by clear rules from regulatory agencies, outlining who is approved for use and who is excluded or restricted.

Category	Official Regulatory Statement
Approved Populations	Adults for all three main indications; Children and adolescents aged 10 years and older for Type 2 Diabetes Mellitus only.
Absolute Contraindications	History of serious hypersensitivity reaction to dapagliflozin; Patients with End-Stage Renal Disease (ESRD) or those on Dialysis; Patients with eGFR less than 30 mL/min/1.73 m^2.
Not Recommended Use	Patients with Type 1 Diabetes Mellitus; Use for improving glycemic control (T2DM) when eGFR is less than 45 mL/min/1.73 m^2; Initiation is not recommended at GFR < 25 mL/min for any indication.
Age and Physiological Status	Not recommended during the second and third trimesters of pregnancy or while breastfeeding. No data is available for children under 10 years of age.

Official regulatory documents define who can and cannot use the medicine by establishing clear exclusion criteria, such as absolute prohibition in cases of severe hypersensitivity or severe renal impairment. Other populations, like those with reduced but not contraindicated kidney function or Type 1 Diabetes, are officially not recommended for treatment, often due to expected lack of efficacy or increased risk as stated in the labeling.

What should I know about interactions with other medicines?

This section outlines the officially documented interaction profile of Forxiga (dapagliflozin), based solely on governmental regulatory information.

Pharmacodynamic (PD) Interactions

Interacting Product Category	Official Regulatory Statement	Constraint/Procedural Note
Diuretics (Thiazide and Loop)	May add to the diuretic effect, increasing the risk of hypotension (volume depletion).	Use is not recommended with Loop Diuretics (SmPC).
Insulin & Insulin Secretagogues	Co-administration increases the risk of hypoglycemia.	Consider lowering the dose of the co-administered agent.
Lithium	May lead to a reduction in serum lithium concentrations due to potential increased renal clearance.	Requires more frequent monitoring of serum lithium levels.

Pharmacokinetic (PK) & Other Constraints

Forxiga is primarily metabolized via UGT1A9 (glucuronide conjugation). This pathway dictates pharmacokinetic changes when co-administered with certain substances:

Rifampin (UGT Inducer) decreases dapagliflozin exposure (Cmax and AUC).
Mefenamic Acid (UGT Inhibitor) increases dapagliflozin exposure.

Official regulatory documents state that use is not recommended in patients concomitantly treated with Pioglitazone (SmPC precautionary measure).

There are no timing-based interaction rules (e.g., must be separated by hours) and no documented clinically significant interaction with food. In patients with severe hepatic impairment, the systemic exposure of dapagliflozin is officially noted to be increased.

Interference with Assays

Monitoring glycaemic control with the 1,5-Anhydroglucitol (1,5-AG) assay is not recommended because measurements are unreliable due to drug interference.

Mechanism of Action

Inhibition of Renal Glucose Reabsorption

Dapagliflozin is a selective, competitive inhibitor of the Sodium-Glucose Co-transporter 2 (SGLT2), a protein located in the S1 segment of the proximal renal tubule responsible for glucose reabsorption. By inhibiting this transporter, the drug initiates a glucosuric cascade, where filtered glucose is not reabsorbed and is consequently excreted in the urine. This action is insulin-independent, operating outside the pathways governing insulin release or sensitivity.

Regulation of Volume Dynamics and Hemodynamics

The molecular blockade of SGLT2 concurrently reduces the reabsorption of sodium, leading to natriuresis (sodium excretion). This sodium loss, coupled with the osmotic loss of water, results in a reduction of the total fluid volume. This volume change influences cardiac hemodynamics by affecting the resistance the heart pumps against (Afterload) and the volume returning to the heart (Preload), thereby reducing myocardial wall stress.

Engagement of Tubuloglomerular Feedback

The increase in sodium delivered to the kidney's macula densa cells engages the Tubuloglomerular Feedback (TGF) mechanism. This feedback loop mediates the constriction of the afferent arteriole, which influences the pressure transmitted to the filtering capillaries. This mechanistic consequence results in a reduction of intraglomerular pressure.

Dosage and Administration Information

Official Administration Guidelines

Forxiga (dapagliflozin) is consistently administered as an oral film-coated tablet in either 5 mg or 10 mg strengths. The medicine is intended for once-daily administration, maintaining a fixed schedule for long-term chronic management. Tablets may be taken with or without food and are to be swallowed whole.

Standard Dosing and Administration Scope

Feature	Guideline
Dosing Schedule (Adults):	10 mg once daily for Chronic Heart Failure and Chronic Kidney Disease. 5 mg once daily as the initial dose for Type 2 Diabetes, potentially increasing to 10 mg.
Missed-Dose Guidance:	If a dose is missed, it should be taken as soon as remembered unless it is almost time for the next dose, in which case the missed dose is skipped. Doses should not be doubled.
Kidney Function Rules:	Initiation is not recommended if the estimated Glomerular Filtration Rate (eGFR) is below 25 mL/min/1.73 m^2.
Liver Function Rules:	Patients with severe hepatic impairment are recommended to start on a 5 mg dose.

Procedural Structure

The official protocol centers on a simple, once-daily oral intake. Before starting treatment, the patient's renal function must be assessed and volume depletion corrected. This pattern establishes a standardized method for continuous use of the medicine, with the only administration variation being the initial dose choice based on the patient's specific indication or organ function.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Forxiga

This overview describes the types of clinical research conducted on Forxiga (dapagliflozin) and the kinds of findings that have been reported by major trials and regulatory bodies. The text focuses only on the structure of the evidence and the main observations, not on individual outcomes or clinical recommendations.

Evidence for Use in Type 2 Diabetes Mellitus

Research examined the observational patterns of dapagliflozin in Type 2 Diabetes Mellitus (T2DM) through numerous short-term and long-term randomized controlled trials (RCTs). These studies were used in research exploring how blood sugar control changes over time. Longer-duration trials were conducted specifically to track major cardiovascular outcomes, focusing on the time to first hospitalization for heart failure (HHF) and the occurrence of cardiovascular events in adult populations.

The findings describe patterns observed in the studies related to how HbA1c values and fasting plasma glucose were monitored. Longer-term trials observed patterns where the rate of reported hospitalizations for heart failure and major cardiovascular events appeared lower in high-risk adult populations compared to the placebo group. Evidence remains limited and heterogeneous concerning dapagliflozin's blood sugar effects in patients with severely reduced kidney function (eGFR below 45 mL/min/1.73 m^2).

Evidence for Use in Chronic Heart Failure

The evidence base for the use of dapagliflozin in Chronic Heart Failure (CHF) is derived from large, event-driven, randomized, placebo-controlled trials. The research monitored populations across the spectrum of LVEF (reduced, preserved, and mildly reduced heart pumping function), regardless of a Type 2 Diabetes diagnosis. The studies monitored a composite endpoint, which combined the time to first event of cardiovascular death or hospitalization for heart failure.

The major event-driven trials observed patterns where the rate of the composite endpoint appeared lower in the dapagliflozin group compared to the placebo group. Studies reported how scores evolved for symptoms and patient-reported assessments of health status based on functional scale assessments.

Evidence for Use in Chronic Kidney Disease

Research for the use of dapagliflozin in Chronic Kidney Disease (CKD) includes a large, dedicated, randomized, placebo-controlled trial. The key outcomes that research examined included a composite of worsening kidney function (such as sustained declines in eGFR) and the occurrence of cardiovascular death in populations both with and without Type 2 Diabetes. The dedicated CKD trial observed patterns where the rate of the composite endpoint appeared lower compared to the placebo group. Findings also indicate patterns related to how Urinary Albumin-to-Creatinine Ratio (UACR) was monitored.

What Remains Uncertain in the Research Record

While major research describes broad patterns, there are recognized limitations. Data for the initiation of treatment in patients with very advanced kidney dysfunction are insufficient. Studies for kidney disease generally excluded patients with certain specific causes of kidney disease, meaning the results apply primarily to the populations studied. Comparative evidence for certain uncommon disease subgroups is sometimes lacking or still emerging. Studies provide context but do not determine whether an individual will respond similarly.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Forxiga (FAQ)

Q: What is the most common dose of Forxiga?

According to official product information, the standard dose strength cited for chronic heart failure and chronic kidney disease is 10 mg once daily. For the treatment of type 2 diabetes, the medicine is available in a starting strength of 5 mg, which may be adjusted up to 10 mg based on the prescribing professional’s direction.

Q: How should I dispose of unused or expired Forxiga?

Official information advises that unused or expired medicine should be disposed of in accordance with local requirements and should not be placed in household waste or flushed down the toilet. The official guidance mentions that drug take-back programs are an option where available.

Q: What are the signs of volume depletion I should look out for?

Volume depletion is a potential effect associated with the drug’s mechanism of action. Regulatory labeling lists symptoms of possible volume depletion, which include dizziness, feeling faint, lightheadedness, and weakness, particularly when standing up.

Q: Is Forxiga (dapagliflozin) safe to use during pregnancy or while breastfeeding?

Official prescribing information advises that the use of Forxiga is generally not recommended during the second and third trimesters of pregnancy. Similarly, the medicine is not recommended for use while breastfeeding.

Q: What should I do if I accidentally take a double dose of Forxiga?

Official labeling states that a double dose should never be taken to compensate for a missed one. If an accidental overdose occurs, consultation with a healthcare professional is necessary.

Q: Can I drink alcohol while I am on Forxiga?

Regulatory documents list alcohol abuse as a factor that may increase the risk of a serious condition called ketoacidosis in patients with diabetes. Alcohol consumption may also interfere with overall blood glucose management, as this may impact overall blood glucose management.

Q: Should I stop taking Forxiga if I get the flu or a serious illness?

Temporary discontinuation of the drug may be considered by a healthcare professional during clinical situations that can increase the risk of ketoacidosis, such as a serious acute illness, prolonged fasting, or major surgery. Consultation with a healthcare professional is advised to determine the appropriate course of action during an illness.

Q: Can I cut or crush the Forxiga tablets if I have trouble swallowing pills?

Official product information describes Forxiga as a film-coated tablet that should be swallowed whole. Regulatory guidance for this medicine and related products generally advises that the tablets should not be cut, crushed, or chewed before swallowing.

Q: Is Forxiga the same as Farxiga?

Yes, they are the same medicine. Official sources confirm that Forxiga and Farxiga both contain the active ingredient dapagliflozin. Forxiga is the brand name used in many countries internationally, while Farxiga is the brand name used for the same product in the United States.

How should Forxiga be stored and disposed of?

Storage and Disposal Requirements for Forxiga (Dapagliflozin)

Storage Conditions

Forxiga tablets must be stored at controlled room temperature, maintained between 20 C and 25 C (68 F to 77 F), with excursions permitted up to 30 C. The product must be kept from freezing and protected from excess heat, moisture, and direct light.

The medication should be stored in its original container, which must be kept tightly closed. Tablets should remain in the blister pack until the time of administration to maintain stability. For safety, the product must be stored out of the sight and reach of children.

Disposal Instructions

Disposal of any unused or expired Forxiga must be completed in accordance with local regulations and pharmaceutical waste guidelines. The medication should not be disposed of via household waste or wastewater, such as flushing down a toilet or pouring down a drain. Patients may utilize a drug take-back program if available, or consult a healthcare professional for guidance on proper disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.